These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25340579)

  • 1. Managing GIST in the imatinib era: optimization of adjuvant therapy.
    Trent JC; Subramanian MP
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New fronts in the adjuvant treatment of GIST.
    Reichardt P; Joensuu H; Blay JY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J; Dang YZ; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy in primary GIST: state-of-the-art.
    Reichardt P; Blay JY; Boukovinas I; Brodowicz T; Broto JM; Casali PG; Decatris M; Eriksson M; Gelderblom H; Kosmidis P; Le Cesne A; Pousa AL; Schlemmer M; Verweij J; Joensuu H
    Ann Oncol; 2012 Nov; 23(11):2776-2781. PubMed ID: 22831984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
    Pan ZZ; Wu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients.
    Joensuu H; Reichardt P; Eriksson M; Sundby Hall K; Vehtari A
    Radiology; 2014 Apr; 271(1):96-103. PubMed ID: 24475826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
    Gronchi A
    Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
    Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
    Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
    Eisenberg BL
    Am J Clin Oncol; 2013 Feb; 36(1):89-90. PubMed ID: 23334483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment of GIST: patient selection and treatment strategies.
    Joensuu H
    Nat Rev Clin Oncol; 2012 Apr; 9(6):351-8. PubMed ID: 22525709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.
    Essat M; Cooper K
    Int J Cancer; 2011 May; 128(9):2202-14. PubMed ID: 21387287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
    Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
    Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
    Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
    Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.